Earnings Releases·Nov 5, 2026, 7:45 AM ET

Viatris — Third Quarter 2026 Earnings Summary

**Financial Results:** Q3 2026 total revenues were $3.75 billion (flat YoY), while adjusted net earnings rose 5% to $821 million ($0.71 EPS) and adjusted EBITDA increased 4% to $1.20 billion; U.S. GAAP net loss widened to $325 million due to higher income tax provisions.
**Guidance Raise:** The company raised midpoints for full-year 2026 guidance across all metrics, including total revenues to $14.8 billion, adjusted EPS to $2.60, and free cash flow to $2.3 billion, citing strong execution and momentum in the base business.
**Strategic M&A:** Viatris entered a definitive agreement to acquire Pacira BioSciences for $1.65 billion ($36.50/share), expected to close by November 2026, with the transaction excluded from current guidance and projected to have minimal impact on the gross leverage ratio.
**Operational Challenges:** Supply constraints in Europe and Emerging Markets, exacerbated by a voluntary manufacturing suspension at the Nashik, India facility following FDA observations, are estimated to impact revenues by approximately $100 million per quarter through Q4 2026, with production expected to resume in Q1 2027.
**Capital Return & Growth:** The company returned $717 million to shareholders year-to-date (including $300 million in buybacks) and expects to deliver $450 million in new product revenues for 2026, driven by recent approvals for RYZUMVI and WAKIX.